Literature DB >> 16169675

Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes?

Theodore Girinsky1, Charlotte Pichenot, Anne Beaudre, Mithra Ghalibafian, Dimitri Lefkopoulos.   

Abstract

PURPOSE: To evaluate the role of beam orientation optimization and the role of virtual volumes (VVs) aimed at protecting adjacent organs at risk (OARs), and to compare various intensity-modulated radiotherapy (IMRT) setups with conventional treatment with anterior and posterior fields and three-dimensional conformal radiotherapy (3D-CRT). METHODS AND MATERIALS: Patients with mediastinal masses in Hodgkin's disease were treated with combined modality therapy (three to six cycles of adriamycin, bleomycin, vinblastine, and dacarbazine [ABVD] before radiation treatment). Contouring and treatment planning were performed with Somavision and CadPlan Helios (Varian Systems, Palo Alto, CA). The gross tumor volume was determined according to the prechemotherapy length and the postchemotherapy width of the mediastinal tumor mass. A 10-mm isotropic margin was added for the planning target volume (PTV). Because dose constraints assigned to OARs led to unsatisfactory PTV coverage, VVs were designed for each patient to protect adjacent OARs. The prescribed dose was 40 Gy to the PTV, delivered according to guidelines from International Commission on Radiation Units and Measurements Report No. 50. Five different IMRT treatment plans were compared with conventional treatment and 3D-CRT.
RESULTS: Beam orientation was important with respect to the amount of irradiated normal tissues. The best compromise in terms of PTV coverage and protection of normal tissues was obtained with five equally spaced beams (5FEQ IMRT plan) using dose constraints assigned to VVs. When IMRT treatment plans were compared with conventional treatment and 3D-CRT, dose conformation with IMRT was significantly better, with greater protection of the heart, coronary arteries, esophagus, and spinal cord. The lungs and breasts in women received a slightly higher radiation dose with IMRT compared with conventional treatments. The greater volume of normal tissue receiving low radiation doses could be a cause for concern.
CONCLUSIONS: The 5FEQ IMRT plan with dose constraints assigned to the PTV and VV allows better dose conformation than conventional treatment and 3D-CRT, notably with better protection of the heart and coronary arteries. Of concern is the "spreading out" of low doses to the rest of the patient's body.

Entities:  

Mesh:

Year:  2005        PMID: 16169675     DOI: 10.1016/j.ijrobp.2005.06.004

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  19 in total

Review 1.  Does radiotherapy still have a place in Hodgkin lymphoma?

Authors:  Joachim Yahalom
Journal:  Curr Hematol Malig Rep       Date:  2009-07       Impact factor: 3.952

2.  Breath-hold technique in conventional APPA or intensity-modulated radiotherapy for Hodgkin's lymphoma: Comparison of ILROG IS-RT and the GHSG IF-RT.

Authors:  Jan Kriz; Max Spickermann; Philipp Lehrich; Heinz Schmidberger; Gabriele Reinartz; Hans Eich; Uwe Haverkamp
Journal:  Strahlenther Onkol       Date:  2015-04-16       Impact factor: 3.621

3.  [Risk of heart failure in patients with Hodgkin lymphoma after radiation and anthracycline chemotherapy].

Authors:  J Kriz; H T Eich
Journal:  Strahlenther Onkol       Date:  2017-08       Impact factor: 3.621

Review 4.  Proton therapy for Hodgkin lymphoma.

Authors:  Michael S Rutenberg; Stella Flampouri; Bradford S Hoppe
Journal:  Curr Hematol Malig Rep       Date:  2014-09       Impact factor: 3.952

Review 5.  Hodgkin lymphoma.

Authors:  Joseph M Connors; Wendy Cozen; Christian Steidl; Antonino Carbone; Richard T Hoppe; Hans-Henning Flechtner; Nancy L Bartlett
Journal:  Nat Rev Dis Primers       Date:  2020-07-23       Impact factor: 52.329

6.  Hodgkin lymphoma, version 2.2015.

Authors:  Richard T Hoppe; Ranjana H Advani; Weiyun Z Ai; Richard F Ambinder; Patricia Aoun; Celeste M Bello; Cecil M Benitez; Philip J Bierman; Kristie A Blum; Robert Chen; Bouthaina Dabaja; Andres Forero; Leo I Gordon; Francisco J Hernandez-Ilizaliturri; Ephraim P Hochberg; Jiayi Huang; Patrick B Johnston; Nadia Khan; David G Maloney; Peter M Mauch; Monika Metzger; Joseph O Moore; David Morgan; Craig H Moskowitz; Carolyn Mulroney; Matthew Poppe; Rachel Rabinovitch; Stuart Seropian; Christina Tsien; Jane N Winter; Joachim Yahalom; Jennifer L Burns; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2015-05       Impact factor: 11.908

Review 7.  Tailored strategies for radiation therapy in classical Hodgkin's lymphoma.

Authors:  Stephanie A Terezakis; Yvette L Kasamon
Journal:  Crit Rev Oncol Hematol       Date:  2012-03-29       Impact factor: 6.312

8.  Clinical relevance of different dose calculation strategies for mediastinal IMRT in Hodgkin's disease.

Authors:  J Koeck; Y Abo-Madyan; H T Eich; F Stieler; J Fleckenstein; J Kriz; R-P Mueller; F Wenz; F Lohr
Journal:  Strahlenther Onkol       Date:  2012-06-29       Impact factor: 3.621

Review 9.  Novel radiotherapy techniques for involved-field and involved-node treatment of mediastinal Hodgkin lymphoma: when should they be considered and which questions remain open?

Authors:  Frank Lohr; Dietmar Georg; Luca Cozzi; Hans Theodor Eich; Damien C Weber; Julia Koeck; Barbara Knäusl; Karin Dieckmann; Yasser Abo-Madyan; Christian Fiandra; Rolf-Peter Mueller; Andreas Engert; Umberto Ricardi
Journal:  Strahlenther Onkol       Date:  2014-09-11       Impact factor: 3.621

10.  Four-dimensional computed tomography-based treatment planning for intensity-modulated radiation therapy and proton therapy for distal esophageal cancer.

Authors:  Xiaodong Zhang; Kuai-le Zhao; Thomas M Guerrero; Sean E McGuire; Brian Yaremko; Ritsuko Komaki; James D Cox; Zhouguang Hui; Yupeng Li; Wayne D Newhauser; Radhe Mohan; Zhongxing Liao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-09-01       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.